With no molecular biomarkers to predict immunotherapy response in metastatic melanoma, Sydney researchers have found that a combination of standard clinical measures such as baseline blood parameters help predict overall survival. In what they say could be a simple and useful tool for clinical decision making, researchers at the Melanoma Institute Australia, University of Sydney ...
Simple risk tool predicts immunotherapy response in melanoma patients
By Michael Woodhead
12 Jun 2019